Back to search results

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Sarcoma · Sarcoma, Ewing · Desmoplastic Small Round Cell Tumor · Refractory Sarcoma · Osteosarcoma · Rhabdomyosarcoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Boston Children's Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (David Shulman, MD) · david_shulman@dfci.harvard.edu · 617-632-6670
    Contact: Principal Investigator (David Shulman, MD)

  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (David Shulman, MD) · David_Shulman@dfci.harvard.edu · 617-632-6670
    Contact: Principal Investigator (David Shulman, MD)

  • Brigham and Women's Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (David Shulman, MD) · david_shulman@dfci.harvard.edu · 617-632-6670
    Contact: Principal Investigator (David Shulman, MD)
Study leads

  • David Shulman, MD

    Principal Investigator

    Dana-Farber Cancer Institute

View source on ClinicalTrials.gov(opens in a new tab)